Considerations in the design of clinical and epidemiological metabolic phenotyping studies

2014 ◽  
pp. 6-19
Author(s):  
Georgios Theodoridis ◽  
Helen G Gika ◽  
Andrew Nicholls ◽  
Ian D Wilson
Keyword(s):  
Metabolic Phenotyping

102 Functional and metabolic phenotyping of the murine heart using an ex vivo perfusion system and 13C-substrates

2003 ◽  
Vol 2 (1) ◽  
pp. 12
Author(s):  
M KHAIRALLAH ◽  
B BOUCHARD ◽  
J MCDUFF ◽  
F LABARTHE ◽  
G DANIALOU ◽  
...  
Keyword(s):  
Ex Vivo ◽  
Perfusion System ◽  
Metabolic Phenotyping ◽  
Ex Vivo Perfusion

Cardio-metabolic phenotyping of patients with familiar hypocalciuric hypercalcemia

2014 ◽  
Author(s):  
Peter Wolf ◽  
Martin Krssak ◽  
Yvonne Winhofer ◽  
Christian Anderwald ◽  
Elisabeth Zwettler ◽  
...  
Keyword(s):  
Metabolic Phenotyping

scholarly journals Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Luke Whiley ◽  
◽  
Katie E. Chappell ◽  
Ellie D’Hondt ◽  
Matthew R. Lewis ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Systemic Inflammation ◽  
Metabolic Phenotyping ◽  
Acid Urine ◽  
Metabolite Concentrations ◽  
Ssri Medication ◽  
The Impact ◽  
Urine And Serum ◽  
Urine Serum

Abstract Background Both serotonergic signalling disruption and systemic inflammation have been associated with the pathogenesis of Alzheimer’s disease (AD). The common denominator linking the two is the catabolism of the essential amino acid, tryptophan. Metabolism via tryptophan hydroxylase results in serotonin synthesis, whilst metabolism via indoleamine 2,3-dioxygenase (IDO) results in kynurenine and its downstream derivatives. IDO is reported to be activated in times of host systemic inflammation and therefore is thought to influence both pathways. To investigate metabolic alterations in AD, a large-scale metabolic phenotyping study was conducted on both urine and serum samples collected from a multi-centre clinical cohort, consisting of individuals clinically diagnosed with AD, mild cognitive impairment (MCI) and age-matched controls. Methods Metabolic phenotyping was applied to both urine (n = 560) and serum (n = 354) from the European-wide AddNeuroMed/Dementia Case Register (DCR) biobank repositories. Metabolite data were subsequently interrogated for inter-group differences; influence of gender and age; comparisons between two subgroups of MCI - versus those who remained cognitively stable at follow-up visits (sMCI); and those who underwent further cognitive decline (cMCI); and the impact of selective serotonin reuptake inhibitor (SSRI) medication on metabolite concentrations. Results Results revealed significantly lower metabolite concentrations of tryptophan pathway metabolites in the AD group: serotonin (urine, serum), 5-hydroxyindoleacetic acid (urine), kynurenine (serum), kynurenic acid (urine), tryptophan (urine, serum), xanthurenic acid (urine, serum), and kynurenine/tryptophan ratio (urine). For each listed metabolite, a decreasing trend in concentrations was observed in-line with clinical diagnosis: control > MCI > AD. There were no significant differences in the two MCI subgroups whilst SSRI medication status influenced observations in serum, but not urine. Conclusions Urine and serum serotonin concentrations were found to be significantly lower in AD compared with controls, suggesting the bioavailability of the neurotransmitter may be altered in the disease. A significant increase in the kynurenine/tryptophan ratio suggests that this may be a result of a shift to the kynurenine metabolic route due to increased IDO activity, potentially as a result of systemic inflammation. Modulation of the pathways could help improve serotonin bioavailability and signalling in AD patients.

scholarly journals Molecular Phenomic Approaches to Deconvolving the Systemic Effects of SARS-CoV-2 Infection and Post-acute COVID-19 Syndrome

Phenomics ◽  
2021 ◽  
Author(s):  
Jeremy K. Nicholson
Keyword(s):  
Molecular Level ◽  
Organ Damage ◽  
Zoonotic Diseases ◽  
Mitigation Strategies ◽  
Health Consequence ◽  
Metabolic Phenotyping ◽  
Persistent Symptoms ◽  
Biological Discovery ◽  
New Biomarkers

AbstractSARS COV-2 infection causes acute and frequently severe respiratory disease with associated multi-organ damage and systemic disturbances in many biochemical pathways. Metabolic phenotyping provides deep insights into the complex immunopathological problems that drive the resulting COVID-19 disease and is also a source of novel metrics for assessing patient recovery. A multiplatform metabolic phenotyping approach to studying the pathology and systemic metabolic sequelae of COVID-19 is considered here, together with a framework for assessing post-acute COVID-19 Syndrome (PACS) that is a major long-term health consequence for many patients. The sudden emergence of the disease presents a biological discovery challenge as we try to understand the pathological mechanisms of the disease and develop effective mitigation strategies. This requires technologies to measure objectively the extent and sub-phenotypes of the disease at the molecular level. Spectroscopic methods can reveal metabolic sub-phenotypes and new biomarkers that can be monitored during the acute disease phase and beyond. This approach is scalable and translatable to other pathologies and provides as an exemplar strategy for the investigation of other emergent zoonotic diseases with complex immunological drivers, multi-system involvements and diverse persistent symptoms.

Metabolic phenotyping of the Yersinia high-pathogenicity island that regulates central carbon metabolism

The Analyst ◽  
2015 ◽  
Vol 140 (10) ◽  
pp. 3356-3361 ◽  
Author(s):  
Leyu Yan ◽  
Wenna Nie ◽  
Haitao Lv
Keyword(s):  
Carbon Metabolism ◽  
Virulence Genes ◽  
Pathogenicity Island ◽  
Central Carbon Metabolism ◽  
Metabolic Phenotyping ◽  
High Pathogenicity ◽  
Central Carbon ◽  
Regulatory Effects

The regulatory effects of the HPI virulence genes on central carbon metabolism differentiate UPEC from non-UPEC.

Metabolic Phenotyping of Traumatized Patients Reveals a Susceptibility to Sepsis

2013 ◽  
Vol 85 (22) ◽  
pp. 10850-10855 ◽  
Author(s):  
Benjamin J. Blaise ◽  
Aurélie Gouel-Chéron ◽  
Bernard Floccard ◽  
Guillaume Monneret ◽  
Bernard Allaouchiche
Keyword(s):  
Metabolic Phenotyping

Metabolic Phenotyping: History, Status, and Prospects

2019 ◽  
pp. 571-583
Author(s):  
John C. Lindon ◽  
Elaine Holmes ◽  
Jeremy K. Nicholson
Keyword(s):  
Metabolic Phenotyping

Conception, Implementation and Operation of Large-Scale Metabolic Phenotyping Centres: Phenome Centres

2019 ◽  
pp. 385-405 ◽  
Author(s):  
Frank W. Bonner ◽  
Lynn Maslen ◽  
John C. Lindon ◽  
Matthew R. Lewis ◽  
Jeremy K. Nicholson
Keyword(s):  
Large Scale ◽  
Metabolic Phenotyping
Sign in / Sign up

Export Citation Format

Share Document